Fairness opinions › By year

Healthcare fairness opinions, 2013

8 public-company healthcare transactions announced in 2013 with a fairness opinion in the SEC filing.

2013 valuation benchmarks

EV / LTM EBITDA
9.2x / 11.9x / 24.3x
Q1 / median / Q3 · n=8
EV / LTM revenue
0.96x / 2.02x / 3.99x
Q1 / median / Q3 · n=8
DCF discount rate (midpoint)
8.0% / 11.0% / 21.0%
Q1 / median / Q3 · n=8

Transactions announced in 2013. Multiples are enterprise value over the last-twelve-months figure disclosed in the filing; the discount rate is the midpoint of the range the banker used in its DCF.

AnnouncedTargetAcquirerSegment EVEV/EBITDAEV/RevDCF rateFairness opinion
2013-12-16 Solta Medical Valeant Pharmaceuticals International Medical Devices and Supplies $293M11.2x1.77x19.6%–23.6% Piper Sandler
2013-11-18 Patheon JLL Partners Pharmaceutical Services $2.6B12.7x2.27x9.0%–11.0% RBC Capital Markets, Jefferies
2013-11-13 Rochester Medical C. R. Bard Medical Devices and Supplies $262M13.1x3.25x16.4%–18.6%
2013-09-24 Greenway Medical Technologies Vista Equity Partners Digital / HealthTech $644M33.9x4.24x9.0%–10.0% J.P. Morgan
2013-08-02 Theragenics Juniper Investment Medical Devices and Supplies $68.0M9.6x0.87x20.0%–24.0% Brown Gibbons Lang Securities
2013-07-30 Health Management Associates Community Health Systems Hospitals $7.3B9.1x1.24x7.0%–8.0% Morgan Stanley, Lazard, UBS
2013-06-24 Vanguard Health Systems Tenet Healthcare Hospitals $4.3B8.1x0.71x7.5%–8.0% J.P. Morgan
2013-04-29 Conceptus Bayer HealthCare Medical Devices and Supplies $1.1B28.0x6.79x9.0%–12.0% Goldman Sachs

← 2012 · 2014 →